AZD9898

AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma[1].

Product Specifications

CAS Number

[2042347-69-1]

UNSPSC

12352005

Target

Glutathione S-transferase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/azd9898.html

Purity

98.01

Solubility

DMSO : ≥ 250 mg/mL

Smiles

O=C([C@@H]1[C@@H](C(C2=NC=C(N(C3=CC(Cl)=C(F)C=C3F)CC(C)(F)C)N=C2OC)=O)C1)O

Molecular Formula

C20H19ClF3N3O4

Molecular Weight

457.83

References & Citations

[1]Munck Af Rosenschöld M, et al. Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S) -2- ({5-[ (5-Chloro-2,4-difluorophenyl) (2-fluoro-2-methylpropyl) amino]-3-methoxypyrazin-2-yl}carbonyl) cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma. J Med Chem. 2019 Aug 30.